WO1998044103A2 - Protein zur inhibierung von apoptose - Google Patents
Protein zur inhibierung von apoptose Download PDFInfo
- Publication number
- WO1998044103A2 WO1998044103A2 PCT/DE1998/000940 DE9800940W WO9844103A2 WO 1998044103 A2 WO1998044103 A2 WO 1998044103A2 DE 9800940 W DE9800940 W DE 9800940W WO 9844103 A2 WO9844103 A2 WO 9844103A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- dna
- flip
- apoptosis
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a protein which is suitable for inhibiting apoptosis, a DNA which encodes such a protein and a method for producing such a DNA.
- the invention further relates to the use of the DNA and the protein and antibodies directed against the protein.
- Apoptosis is programmed cell death. This is e.g. used by the immune system to ward off harmful substances such as viruses. To do this, virus-specific T lymphocytes attack those cells in the body that are virus-infected and kill them by releasing apoptosis-induced proteins such as perforin.
- the T lymphocytes can also express the CD95 (APO-1 / Fas) ligand, as a result of which cell death occurs via the CD95 pathway. This route involves binding of the CD95 ligand to the CD95 receptor, which then interacts with the adapter protein FADD, thereby inducing the "recruitment” and activation of the protease FLICE at the DISC ("Death-Inducing Signaling Complex").
- the present invention is therefore based on the object of providing an agent with which apoptosis can be inhibited. According to the invention, this is achieved by the subject matter in the claims.
- the present invention thus relates to a protein which is suitable for inhibiting apoptosis, the protein having the amino acid sequence of FIG.
- the present invention is based on the knowledge of the applicant that in animals, especially mammals, especially humans, there is a protein which can inhibit apoptosis.
- This protein comprises the amino acid sequence of FIG. 1 or an amino acid sequence different therefrom by one or more amino acids.
- the applicant has also recognized that the protein interacts with the adapter protein FADD, as a result of which the "recruitment” and the activation of the protease FLICE at the DISC are inhibited.
- FLIP FLICE inhibitor protein
- Another object of the present invention is a coding for FLIP
- Nucleic acid This can be an RNA or a DNA.
- the latter can e.g. be a genomic DNA or a cDNA.
- a DNA is preferred which comprises the following:
- hybridizing DNA indicates a DNA which, under normal conditions, in particular at 20 ° C. below the melting point of the DNA, also DNA from (a) hybridizes.
- the DNA of FIG. 1 was obtained from the DSM (German Collection of Microorganisms and Cell Cultures) as C-FLIP / 2 / W23795 and C-FLIP / 1 / AA1 1 5792 under DSM 1 1488 and DSM 1 1487 on March 25th 1 997 deposited.
- DSM German Collection of Microorganisms and Cell Cultures
- a DNA according to the invention is described below in the form of a cDNA. This is an example of every DNA covered by the present invention.
- a cDNA according to the invention can be produced by customary methods.
- a cDNA according to the invention can be present in a vector or expression vector.
- examples of such are known to the person skilled in the art.
- an expression vector for E. coli these are e.g. pGEMEX, pUC derivatives, pGEX-2T, pET3b and pQE-8.
- yeast e.g. to call pY100 and Ycpad l
- animal cells e.g. pKCR, pEFBOS, cDMB, pCEV4 and pEFrsFLAG must be specified.
- the baculovirus expression vector pAcSGHisNT-A is particularly suitable for expression in insect cells.
- suitable cells for expressing a cDNA according to the invention which is present in an expression vector.
- suitable cells include the E. coli strains HB1 01, DH 1, x1 776, JM 1 01, JM 109, BL21 and SG 1 3009, the yeast strain Saccharomyces cerevisiae and the animal cells L, 3T3, FM3A, CHO, COS, Vero, HeLa and BJAB as well as the insect cells sf9.
- a cDNA according to the invention is converted into a Expression vector must be inserted. He is also aware that this DNA can be inserted in conjunction with a DNA coding for another protein or peptide, so that the cDNA according to the invention can be expressed in the form of a fusion protein.
- Another object of the present invention is an antibody directed against an above protein or fusion protein.
- Such an antibody can be prepared by conventional methods. It can be polyclonal or monoclonal. It is cheap to make it, especially animals
- the present invention makes it possible to investigate apoptosis and its effects, in particular in certain diseases, such as AIDS, autoimmune diseases and neurodegenerative diseases, in detail.
- a nucleic acid according to the invention in particular a DNA, and primers derived therefrom, it can be determined in mammals, in particular humans, whether they contain and / or express a gene which codes for a FLIP protein in the above sense.
- the person skilled in the art uses customary methods such as
- kits which contains a protruding nucleic acid, in particular DNA, and / or primers derived therefrom as well as carriers and customary auxiliaries.
- the present invention is also suitable for inhibiting apoptosis. This is particularly important for diseases such as AIDS and neurodegenerative diseases.
- a FLIP protein according to the invention can be introduced into mammals, especially humans. For this purpose, it may be beneficial to use FLIP on a protein that is not considered foreign by the respective body, e.g. Transferrin or BSA to couple.
- a nucleic acid according to the invention, in particular a DNA can also be introduced into mammals, in particular humans, and expressed there. For this purpose, it may be advantageous to place the expression of the nucleic acid according to the invention under the control of a tissue-specific promoter. Vectors necessary for the expression of a
- Nucleic acid in mammals are known to those skilled in the art. Furthermore, the expression of FLIP can be controlled and regulated with an antibody according to the invention. The antibody can also be present in the kit above.
- the present invention thus represents a major contribution to the diagnostic and therapeutic detection of apoptotic processes.
- the diagnostic detection can take place not only post- but also prenatally.
- FIG. 1 shows the base sequence and the amino acid sequence derived therefrom, which is comprised by a FLIP protein according to the invention.
- the outlined sequence gives a DED (Death Effector Domain) -
- Fig. 1 is found in DSM 1 1 488.
- 2 shows the base sequence and the amino acid sequence derived therefrom which is encompassed by a FLIP protein according to the invention.
- the sequence of Fig. 2 can be found in DSM 1 1487.
- FIG. 3 shows in (A) the expression of a FLIP protein according to the invention in cells. Due to the FLAG tag portion, the FLIP protein according to the invention (FLIP-FLAG) shows a slower running behavior than the FLIP protein expressed endogenously by the cells.
- FLIP-FLAG shows a slower running behavior than the FLIP protein expressed endogenously by the cells.
- Example 1 Production and purification of a FLIP protein according to the invention
- the DNA from FIG. 1 is provided with Bam HI linkers, cut with Bam HI and inserted into the expression vector pQE-8 (Diagen) cleaved with Bam HI.
- the expression plasmid pQ / FLIP is obtained.
- pQ / FLIP is used to transform E.coli SG 1 3009 (cf. Gottesmann, S. et al., J. Bacteriol. 148, (1 981), 265-273).
- the bacteria are in an LB medium with 10 ⁇ g / ml ampicillin and
- the bound fusion protein is eluted in a pH 3.5 buffer. After neutralization, the fusion protein is a 1 8% SDS polyacrylamide Subject to gel electrophoresis and stained with Coomassie blue (cf. Thomas, JO and Kornberg, RD, J. Mol. Biol. 1 49 (1 975), 709-733).
- Example 2 Production and detection of an antibody according to the invention
- a fusion protein according to the invention from example 1 is subjected to a 1 8% SDS-polyacrylamide gel electrophoresis. After staining the gel with 4 sts
- 35 ⁇ g of gel-purified fusion protein in 0.7 ml of PBS and 0.7 ml of complete or incomplete Freund's adjuvant are used per immunization.
- the rabbit's serum is tested in an immunoblot.
- a fusion protein according to the invention from Example 1 is subjected to an SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose filter (cf. Khyse-
- the western Blot analysis is carried out as in Bock, C.-T. et al., Virus Genes 8, (1 994), 21 5-229.
- the nitrocellulose filter is incubated with a first antibody at 37 ° C. for 1 h.
- This antibody is rabbit serum (1: 1 000 in PBS).
- the nitrocellulose filter is incubated with a second antibody.
- This antibody is an alkaline phosphatase-linked monoclonal goat anti-rabbit IgG antibody (Dianova) (1: 5000) in PBS.
- Antibodies are extracted from egg yolk and tested in a Western blot. Polyclonal antibodies according to the invention are detected.
- Example 3 Expression of a FLIP protein according to the invention in cells and its action
- the DNA of FIG. 2 is provided with ExoR5 / Xbal linkers, cut with EcoRI and Xbal and inserted into the expression vector pEFrsFLAG cleaved with the same restriction enzymes.
- the expression plasmid pEFrsFLAG-FLIP is obtained. This codes for a fusion protein FLAG-FLIP from a FLAG tag (N-terminus partner) and the FLIP protein according to the invention from FIG. 2 (C-terminus partner).
- pEFrsFLAG-FLIP is used to transfect human BJAB cells. Extracts are obtained from transfected cells and electrophoresed on an SDS polyacrylamide gel. A Western blot method is then carried out in which a monoclonal antibody from Example 2 is used for the detection of the expressed FLIP protein. An anti-mouse antibody is used to detect the antibody binding (cf. FIG. 3A).
- a FLIP protein according to the invention can be expressed in cells and detected by an antibody according to the invention.
- the above BJAB cells transfected with pEFrs FLAG-FLIP are treated untreated or treated with 10 ng / ml anti-APO-1 for 16 hours at 37 ° C. Treatment with anti-APO-1 mediates CD95
- the amount of apoptotic cells is determined by determining the DNA fragmentation (see FIG. 3B).
- CD95-mediated apoptosis can be inhibited by the expression of the FLIP protein according to the invention.
- BJAB cells and BJAB cells transfected with pEFrsFLAG-FLIP are treated with 1 ⁇ g / ml anti-APO-1.
- Cell extracts are obtained and electrophoretically separated in an SDS polyacrylamide gel.
- a Western blot method is then carried out, in which an antibody directed against the protease FLICE is used (cf. FIG. 3C).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98928120A EP0973903A2 (de) | 1997-04-01 | 1998-04-01 | Protein zur inhibierung von apoptose |
JP54106998A JP2001521378A (ja) | 1997-04-01 | 1998-04-01 | アポトーシスを阻害するためのタンパク質 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19713434.3 | 1997-04-01 | ||
DE19713434A DE19713434C1 (de) | 1997-04-01 | 1997-04-01 | Protein zur Inhibierung von Apoptose |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998044103A2 true WO1998044103A2 (de) | 1998-10-08 |
WO1998044103A3 WO1998044103A3 (de) | 1999-03-18 |
Family
ID=7825130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1998/000940 WO1998044103A2 (de) | 1997-04-01 | 1998-04-01 | Protein zur inhibierung von apoptose |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0973903A2 (de) |
JP (1) | JP2001521378A (de) |
DE (1) | DE19713434C1 (de) |
WO (1) | WO1998044103A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000003023A1 (en) * | 1998-07-08 | 2000-01-20 | Merck Frosst Canada & Co. | Usurpin, a mammalian ded-caspase homologue that precludes caspase-8 recruitment and activation by the cd-95 (fas, apo-1) receptor complex |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018133937A1 (en) * | 2017-01-19 | 2018-07-26 | Biontech Ag | Engineered cells for inducing tolerance |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998031801A1 (en) * | 1997-01-21 | 1998-07-23 | Human Genome Sciences, Inc. | I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and cd-95 induced apoptosis |
WO1998033883A1 (en) * | 1997-02-05 | 1998-08-06 | Tularik, Inc. | Regulators of apoptosis |
WO1998039435A1 (en) * | 1997-03-03 | 1998-09-11 | Yeda Research And Development Co. Ltd. | Cash (caspase homologue) with death effector domain, modulators of the function of fas receptors |
-
1997
- 1997-04-01 DE DE19713434A patent/DE19713434C1/de not_active Expired - Fee Related
-
1998
- 1998-04-01 JP JP54106998A patent/JP2001521378A/ja active Pending
- 1998-04-01 WO PCT/DE1998/000940 patent/WO1998044103A2/de not_active Application Discontinuation
- 1998-04-01 EP EP98928120A patent/EP0973903A2/de not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998031801A1 (en) * | 1997-01-21 | 1998-07-23 | Human Genome Sciences, Inc. | I-flice, a novel inhibitor of tumor necrosis factor receptor-1 and cd-95 induced apoptosis |
WO1998033883A1 (en) * | 1997-02-05 | 1998-08-06 | Tularik, Inc. | Regulators of apoptosis |
WO1998039435A1 (en) * | 1997-03-03 | 1998-09-11 | Yeda Research And Development Co. Ltd. | Cash (caspase homologue) with death effector domain, modulators of the function of fas receptors |
Non-Patent Citations (7)
Title |
---|
EMEST11 DATABASE Accession number W23795 Hillier L. et al. 09-MAY-1996 (Rel. 47, Created) XP002090524 * |
GOLTSEV Y V ET AL: "CASH, A NOVEL CASPASE HOMOLOGUE WITH DEATH EFFECTOR DOMAINS" JOURNAL OF BIOLOGICAL CHEMISTRY, Bd. 272, Nr. 32, 8. August 1997, Seiten 19641-19644, XP002071903 * |
HAN D K M ET AL: "MRIT, A NOVEL DEATH-EFFECTOR DOMAIN-CONTAINING PROTEIN, INTERACTS WITH CASPASES AND BCLXL AND INITIATES CELL DEATH" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, Bd. 94, Nr. 21, 14. Oktober 1997, Seiten 11333-11338, XP002071904 * |
IRMLER M ET AL: "Inhibition of death receptor signals by cellular FLIP " NATURE, JUL 10 1997, 388 (6638) P190-5, XP002063886 ENGLAND * |
MUZIO M ET AL: "FLICE, A NOVEL FADD-HOMOLOGOUS ICE/CED-3-LIKE PROTEASE, IS RECRUITED TO THE CD95 (FAS/APO-1) DEATH-INDUCING SIGNALING COMPLEX" CELL, Bd. 85, Nr. 6, 14. Juni 1996, Seiten 817-827, XP002035464 * |
SRINIVASULA S M ET AL: "FLAME-1, A NOVEL FADD-LIKE ANTI-APOPTOTIC MOLECULE THAT REGULATES FAS/TNFR1-INDUCED APOPTOSIS" JOURNAL OF BIOLOGICAL CHEMISTRY, Bd. 272, Nr. 30, 25. Juli 1997, Seiten 18542-18545, XP002071905 * |
THOME M ET AL: "Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors." NATURE, APR 3 1997, 386 (6624) P517-21, XP002090523 ENGLAND * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000003023A1 (en) * | 1998-07-08 | 2000-01-20 | Merck Frosst Canada & Co. | Usurpin, a mammalian ded-caspase homologue that precludes caspase-8 recruitment and activation by the cd-95 (fas, apo-1) receptor complex |
Also Published As
Publication number | Publication date |
---|---|
WO1998044103A3 (de) | 1999-03-18 |
DE19713434C1 (de) | 1998-09-24 |
EP0973903A2 (de) | 2000-01-26 |
JP2001521378A (ja) | 2001-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE19747418C1 (de) | Inhibitor-Protein des wnt-Signalwegs | |
DE19521046C1 (de) | Protein mit DNase-Aktivität | |
WO1998044103A2 (de) | Protein zur inhibierung von apoptose | |
DE19611234C1 (de) | Tyrosin-Phosphatase-verwandtes Protein | |
EP1015583B1 (de) | Srcr domäne-enthaltendes protein | |
DE19527552C2 (de) | Transketolase-verwandtes-Protein | |
DE19534763C1 (de) | FMR1-verwandtes Protein | |
DE19825621C2 (de) | Protein zur Regulation von Apoptose | |
DE19650758C1 (de) | PKD1-Fragmente mit Bindungsregionen für PKD1-spezifische Antikörper | |
DE19730997C1 (de) | SRCR Domäne-enthaltendes Protein | |
DE19856882C1 (de) | Spermatogenese-Protein | |
WO1999053091A9 (de) | Gdnf-kodierende dna, teile davon und gdnf-varianten | |
DE19847364C1 (de) | Tumor-Protein | |
DE19845277C1 (de) | Transmembran-Protein | |
DE19835910C1 (de) | Gen isoliert auf dem kurzen Arm des menschlichen Chromosoms 17 | |
DE19644501A1 (de) | GABA¶A¶-Rezeptoruntereinheit epsilon-verwandtes Protein | |
DE19818680C1 (de) | DNA-Doppelstrangbruch-Reparatur-Protein | |
EP1073751A2 (de) | Polypeptid mit immunogenen eigenschaften und veränderten biologischen funktionen eines proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 541069 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998928120 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998928120 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998928120 Country of ref document: EP |